TSXV:CZO - Post Discussion
Post by
prophetoffactz on Mar 31, 2024 9:23am
Hypoparathyroidism
According to AEZS's website expected to be a US$2.7 billion market by 2028.
That's a nice, big, fat juicy reward... $US2.7 billion.
What's the risk in the risk/reward? AEZS's product uses an already approved product(parathyroid hormone) to treat the hypoparathyroidism as part of its product and this may also mean abbreviated testing. It could mean going from daily injections to injections once every 1-2 weeks and the current daily injections also wear off during the day with health consequences. It works preclinically.
"Aeterna’s lead development candidate, AEZS-150, is a proprietary fusion protein consisting of a modified growth hormone binding protein (GHBP) linked to parathyroid hormone PTH1-34 with the goal to provide a PTH analog with delayed clearance of one or two weeks." "Meet with regulatory authorities to determine the development path forward; Company expects such a meeting in Q4/2023, and as outcome, an abbreviated safety and toxicology program as the active principle ([1-34]-PTH fragment) is already approved and in use."
"Initiate IND-enabling preclinical studies in 2024."
Be the first to comment on this post